INDIANAPOLIS (AP) – Drug developer Eli Lilly and Co. said Friday the Food and Drug Administration approved Cymbalta as a treatment for chronic musculoskeletal pain.
The drug is already approved for four other uses, including major depressive disorder, generalized anxiety disorder, and chronic low back pain.
Eli Lilly reported $825.3 million in Cymbalta sales during the third quarter.
Originally reported by WISH-TV News. Read the original article here.